Clinical Trials Logo

Peripheral Arterial Disease clinical trials

View clinical trials related to Peripheral Arterial Disease.

Filter by:

NCT ID: NCT00751283 Withdrawn - Clinical trials for Peripheral Vascular Disease

Radiofrequency for the Treatment of Peripheral Vascular Occlusive Disease of the Lower Extremities

Start date: August 2007
Phase: Phase 2/Phase 3
Study type: Interventional

The purpose of this study is to evaluate the safety and efficacy of the Minnow Medical GRST Peripheral Catheter System in the treatment of new lesions in the superficial femoral artery or the popliteal artery.

NCT ID: NCT00672698 Withdrawn - Clinical trials for PERIPHERAL VASCULAR DISEASES

Evaluation of Surgical Risk in Elderly Patients Submitted to Elective Surgery

Start date: November 2008
Phase: N/A
Study type: Observational

The purpose of this study is to establish the surgical risk factors and differences between different diseases in elderly patients submitted to elective surgery in our institution.

NCT ID: NCT00657514 Withdrawn - Clinical trials for Peripheral Arterial Disease

Ranolazine Versus Placebo Effects on Exercise Tolerance in Patients With Heart Disease and Peripheral Arterial Disease

Start date: May 2008
Phase: Phase 4
Study type: Interventional

After 6 weeks of maximal Ranolazine therapy, tissue hemoglobin desaturation kinetics will change compared to placebo in patients with chronic angina and peripheral arterial disease.

NCT ID: NCT00569686 Withdrawn - Clinical trials for Peripheral Artery Disease

Lovaza Therapy of Peripheral Arterial Disease

Start date: September 2007
Phase: N/A
Study type: Interventional

Sixty patients with mild-to-moderate PAD (ABI 0.4-0.9) and hypertriglyceridemia (>200 mg/dl) already treated with statins will be imaged at baseline and randomized to Lovaza and placebo for 12 months. MR imaging will be repeated at the end of the 12-month period. We hypothesize that treatment of hypertriglyceridemia in patients with PAD with Lovaza will reduce atherosclerotic plaque volume in the superficial femoral artery (SFA) by 2% over 1 year compared to placebo. Secondary aims will be to show improved plaque characteristics (thickened fibrous cap, reduced lipid-rich necrotic core, improved exercise calf muscle perfusion using first-pass contrast enhanced MRI and improved exercise treadmill performance with Lovaza compared to matching placebo.